73.12 - 76.25
11.54 - 95.21
Echofin Members Consensus
do you think they are in anyway of a threat to MRNA future govt funding? or has absolutely nothing to do with them? > @MT said: if you have touched KODK today made money or lose money, you gambled. There is no chart that can be followed or logic atm on it so I didnt touch it. i will not touch it until it settles and gives us some of idea of what it can do and cant do. be safe, no fomo.
Next Dividend Date
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
CEO: Stéphane Bancel
HQ: 200 Technology Square Cambridge, 02139 MA